Anticancer Drug Combinations, Studies from Different Pathways

Abstract

Most cancer therapies are seldom effective by single anticancer drug based on multiple genetic alterations and molecular abnormalities. Anticancer drug combination utilities need to transform from empirical to science-guided enterprises. This editorial offers the background knowledge of drug combination therapies by mathematical enquiry. Possible future landscapes and drawbacks of current cancer drug combinative therapy are addressed and speculated.